

# CRISPR/Cas9 Genome-Editing System in Human Stem Cells: Current Status and Future Prospects

Zhao Zhang,<sup>1</sup> Yuelin Zhang,<sup>1</sup> Fei Gao,<sup>1</sup> Shuo Han,<sup>1</sup> Kathryn S. Cheah,<sup>3</sup> Hung-Fat Tse,<sup>1,2</sup> and Qizhou Lian<sup>1,2,3</sup>

<sup>1</sup>Department of Medicine, University of Hong Kong, Hong Kong, China; <sup>2</sup>Shenzhen Institutes of Research and Innovation, University of Hong Kong, Shenzhen, China;

<sup>3</sup>School of Biomedical Sciences, University of Hong Kong, Hong Kong, China

**Genome-editing involves the insertion, deletion, or replacement of DNA in the genome of a living organism using “molecular scissors.” Traditional genome editing with engineered nucleases for human stem cells is limited by its low efficiency, high cost, and poor specificity. The CRISPR system has recently emerged as a powerful gene manipulation technique with advantages of high editing efficiency and low cost. Although this technique offers huge potential for gene manipulation in various organisms ranging from prokaryotes to higher mammals, there remain many challenges in human stem cell research. In this review, we highlight the basic biology and application of the CRISPR/Cas9 system in current human stem cell research, discuss its advantages and challenges, and debate the future prospects for human stem cells in regenerative medicine.**

## Background

CRISPR is a short and repeating nucleotide initially found in the genome of bacteria and archaea, and it functions to eliminate exogenous genetic elements (EGEs) that combine with Cas proteins.<sup>1,2</sup> Three steps are required to eliminate EGEs: new spacer integration, CRISPR/Cas combination, and degeneration (Figure 1). First, some short nucleotides of invaders may integrate with the CRISPR loci of the host as new spacers. The CRISPR RNAs (crRNAs) are then transcribed to generate a crRNA/Cas complex. Finally, the EGEs will be inactivated by the complexes under the base complementation pairing rule. To date, three types of CRISPR-Cas immune system have been identified with different CRISPR repeat sequences and Cas protein profile.<sup>3–5</sup> Among them, the type II CRISPR-Cas9 immune system offers strong potential in developing a totally novel genome-editing tool for biological and medical study because it utilizes RNase III in crRNA transcription and requires just one Cas9 protein to form a crRNA/Cas9 complex.<sup>5</sup> Almendros’s group<sup>6</sup> identified the conservative NGG motif, proto-spacer adjacent motif (PAM), after comparing the CRISPR array of *Streptococcus pyogenes*. In 2013, two articles revealed a new genome-editing stage for biological and biomedical studies.<sup>7,8</sup>

## Principle

Guide RNA (gRNA) and Cas9 nuclease are core components of the CRISPR/Cas9 genome-editing system (Figure 2). Unlike the original type II CRISPR-Cas immune system, its crRNA is eventually simpli-

fied to the shortest mature and functional structure without the original crRNA processing.<sup>7,8</sup> This simplified gRNA contains two parts: a variable region and a basic scaffold. The former normally is composed of 18–20 nucleotides that can bind the target DNA according to the base complementation pairing rule. The latter is a long scaffold-like RNA used to bind Cas9 nuclease and form a gRNA/Cas9 complex. Then, the genome-editing system still requires three nucleotides containing a PAM, NGG.<sup>6</sup> Only the genome DNA that contains PAMs can be identified and bound by the gRNA/Cas9 complex to generate double-strand breaks (DSBs).

## Advantages

The CRISPR/Cas9 genome-editing system offers several advantages over the zinc-finger nucleases (ZFNs) and transcription activator-like effector nuclease (TALEN) in human pluripotent stem cells (PSCs) and somatic stem cells (SSCs). First, CRISPR/Cas9 is more user-friendly than ZNF and TALEN. Several gRNAs such as synthesizing primers need to be selected for using CRISPR/Cas9, because its specificity is related only to ribonucleotide complex formation.<sup>7,8</sup> Second, CRISPR/Cas9 is more economical because there is little associated cost for plasmid-mediated CRISPR/Cas9. Third, as the fastest currently available genome-editing technique, genome editing using CRISPR/Cas9 can typically be achieved in 2 weeks.<sup>9</sup> Finally, CRISPR/Cas9 shows a higher editing efficiency than TALEN in human stem cells. Ding et al.<sup>10</sup> demonstrated the highest genome-editing efficiency of 79% using CRISPR/Cas9 to edit human PSCs.


## Applications in Stem Cell Studies

CRISPR/Cas9-based gene manipulation, for example, gene knockout, gene knockin, gene interference or activation, and other chromosome-related applications, has been widely utilized in biological and biomedical research.<sup>11</sup> Stem cells are indispensable for repair and maintenance of homeostasis. In terms of tissue repair and regeneration capacity, stem cell-mediated cell therapy and gene therapy are regarded as core components of human medicine. Inordinate manpower and financial resources have been poured into stem cell-related studies with many achievements. To date, several types of

<https://doi.org/10.1016/j.omtn.2017.09.009>

**Correspondence:** Qizhou Lian, MD, PhD, Cardiology Division, Department of Medicine, University of Hong Kong, Hong Kong 000000, China.

**E-mail:** [qzlian@hku.hk](mailto:qzlian@hku.hk);



stem cells have been approved for clinical treatments, and many have demonstrated remarkable outcomes in clinical trials.<sup>12</sup> Increasing reports confirm that CRISPR/Cas9 genome editing is a powerful tool that can promote stem cell research, from basic biological to translational studies (Table 1).

### Basic Biological Studies


**Gene Knockout.** The basic biology of PSCs has always been a fundamental component of stem cell and human developmental research. In addition, the high differentiation capacity of human PSCs enables their broad application. It is therefore essential to explore the intrinsic connection between the upstream regulatory mechanism and the downstream biological features. This can be achieved by adopting a classic gene knockout strategy. CRISPR/Cas9 can be used to rapidly induce gene mutations in human PSCs without changing their genetic background, making CRISPR/Cas9 a superior technique to other gene-interfering tools (ZFN, TALEN, and RNAi).<sup>9</sup> When a cell's genome DNA is broken by a gRNA/Cas9 complex, the genome repair system is activated. One such system is non-homologous end joining (NHEJ). This will directly ligate the broken DNA and result in the chance of introducing a wrong base-pair deletion or insertion for gene knockout.<sup>9</sup> Batista et al.<sup>13</sup> used CRISPR/Cas9 to knock out *Mettl3* in order to erase m6A modification in human embryonic stem cells (ESCs), which prevented the self-renewal of ESCs and

**Figure 1. Overview of CRISPR-Cas Immune System**

When EGEs invade the host, some fragments will integrate into the CRISPR loci as a new spacer casually that is co-expressed with Cas nucleases to form Cas/crRNA complexes. These complexes can identify and bind with the same EGEs during a subsequent invasion following the base complementation pairing rule and then finally break the EGEs.

finally promoted lineage differentiation. Wang et al.<sup>14</sup> identified the essential role of P53 in mes-endodermal differentiation through activation of the Wnt3 pathway in human ESCs. Some inducible gene knockout systems that can knock out single or multiple genes at all the stages of cell differentiation have recently been developed in human PSCs.<sup>15,16</sup>

**Controlling Expression.** Although genome-editing-based gene knockout offers a mean by which to study gene function, a less complex method is sometimes required. "Dead" Cas9 (dCas9) is a variant of Cas9 nuclease whose endonucleolytic activity has been removed. It nonetheless retains the capacity to generate the gRNA/Cas9 complex for binding with the targeted DNA regions.<sup>17</sup> Kearns et al.<sup>18</sup> fused different effector domains (VP64 or KRAB) to the dCas9 and provided a platform to control gene expression (transcription repression or activation, CRISPRi/a) in human ESCs. In addition to straightforward controlling styles, an inducible CRISPRi/a has been developed for human stem cell research. Mandegar et al.<sup>19</sup> fused a doxycycline-inducible dCas9 with KRAB and achieved conditional and reversible interference in human induced PSCs (iPSCs) and its derived somatic cells such as cardiac progenitors, cardiomyocytes, and T lymphocytes. Guo et al.<sup>20</sup> designed a doxycycline-inducible dCas9-VPR cassette to activate gene expression in human PSCs. These CRISPRi/a platforms should provide a more convenient strategy to explore gene functions and signaling pathways in human stem cell research, which are faster, more convenient, and more economical than other techniques such as RNAi and gene overexpression.<sup>21</sup> To achieve this, it is necessary to ligate primer-like gRNAs into plasmids to achieve rapid transcription activation or suppression without setting various controls or cDNA cloning, both of which are time consuming in RNAi or gene overexpression. For example, Liu et al.<sup>22</sup> utilized CRISPRi to interrupt the expression of long non-coding RNA (lncRNA) *LOC646329* to reveal its key function in the proliferation of radial glial cells. Luo et al.<sup>23</sup> found that suppression of miR-199a/214 cluster could significantly increase the tumor tropism in human iPSC-derived neural stem cells (NSCs). Similarly, CRISPRa may improve survivability of stem cells by controlling their gene expression following transplantation.<sup>24</sup> CRISPRi/a is highly specific in targeting human stem cells. But



**Figure 2. Schemata of CRISPR/Cas9 Genome-Editing System**

gRNA contains a variable region (red nucleotides) and a basic scaffold structure (blue nucleotides). The former is complementary with one strand of targeted genome DNA that should be adjacent to PAM (NGG, green one). The basic scaffold nucleotide is then targeted to combine and support Cas9 nuclease to generate gRNA/Cas9 complexes. Finally, the targeted genome DNA will be cut at the third nucleotide from PAM (between G and C).

because it targets transcription, it cannot be utilized in the study of alternative splicing.

**Genome-wide Screening.** CRISPR/Cas9 has been used for genome-wide and high-throughput genetic screening in mammalian cells.<sup>25,26</sup> gRNA libraries have been generated to provide large volumes of genes for analyzing results through sequencing data collection and offer an alternative to the traditional RNAi library. Nonetheless, there may be differences in the response of the gene regulatory network, because RNAi knocks down gene expression at the mRNA level, whereas CRISPR/Cas9 targets gene knockout or transcription inhibition.<sup>27</sup> Technically, a virus mixture that contains thousands of gRNAs is produced to co-infect human stem cells with Cas9- or dCas9-expressed virus to simultaneously target thousands of genes to screen for those of interest. CRISPR/Cas9-mediated genome-wide screening strongly supports the basic biological research of human stem cells. Shalem et al.<sup>28</sup> built a CRISPR/Cas9 lentiviral library to simultaneously knock out 18,080 genes in human ESCs and identified many essential genes that are involved in cell survival. Liu et al.<sup>29</sup> identified 326 functional loci of lncRNAs in human iPSCs using the CRISPRi lentivirus library. It is clear that this genetic screening platform has the potential to reveal novel functional genes and a particular signaling pathway,<sup>30</sup> and should be a powerful platform for stem cell research.

**Gene Knockin.** Specific markers are extremely important for stem cell research and indispensable during stem cell differentiation, transplantation in vivo, and in vitro tracing. Normally, identification of a specific marker requires substantial time and energy, but CRISPR/Cas9 has enabled vast improvements. It is now possible to easily and rapidly create a specific marker by fusing epitope tags or fluorescent proteins to the genes of interest.<sup>31,32</sup> With the exception of NHEJ, homology-directed repair (HDR) is another mechanism by which exogenous nucleotide sequences can be introduced into the genome through homologous recombination.<sup>33</sup> DSBs caused by CRISPR/Cas9 significantly promote the homologous recombination between a targeted genome and exogenous DNA fragments to activate HDR

at a cell level.<sup>9,34</sup> For stem cell differentiation, Adkar et al.<sup>35</sup> used CRISPR/Cas9 to generate a COL2A1-GFP reporter human iPSC line to differentiate and purify chondrogenic cells by fusing a GFP to COL2A1, which can co-express GFP protein with COL2A1 protein. Similarly, Hunt et al.<sup>36</sup> built a DARPP-32-GFP cell line to monitor the pharmacological profile of striatal cultures in human medium spiny neurons (MSNs).

**Other Applications.** Genomic imaging is indispensable to genetic and cell biology study. CRISPR/Cas9 can also be used to visually monitor the status of the genome during the cell cycle. Chen et al.<sup>37</sup> modified the original nucleotide sequences of gRNA scaffold to improve its binding ability with genome DNA, and fused the GFP to the C terminus of dCas9 nuclease to finally form a live image to monitor the dynamics of the genome in the cell cycle. This technique can image fixed or living cells with single or multiple colors. It may also be used to monitor the genomic activity of stem cells. Anton et al.<sup>38</sup> imaged the chromatin of mouse ESCs using this method.

#### **Disease Model and Drug Screening**

Traditional animal disease models are important to human biological and biomedical studies. Nonetheless, it is difficult to simulate the real situation in a human body because of species differences. Human PSCs can overcome this limitation. CRISPR/Cas9 helps to easily and rapidly introduce a gene mutation into human stem cells to model a human disease, and avoids ethical problems and those associated with species differences. Indeed, the CRISPR/cas9 system has been shown to be an effective method for drug screening in human stem cell disease models (Table 1).

**Human PSCs.** Human PSCs, including ESCs and iPSCs, are ideal targets for gene knockout because they are easily expanded for further experiments from a single cell culture after resistance selection without losing their pluripotency.<sup>9</sup> One straightforward strategy is to knock out disease-relevant genes in human PSCs using CRISPR/Cas9 in order to explore the pathogenic mechanism in the derived cells (somatic cells, SSCs, and even tumor cells) and for drug screening. *Rb1* is known to initiate retinoblastoma in humans.<sup>39</sup> *Rb1* null human ESCs generated by CRISPR/Cas9 showed aberrant mitochondria and were shown by drug screening to be sensitive to

**Table 1. Summary of CRISPR/Cas9 Utilized in Human Stem Cell Research**

	Cell Type	Function	Year	References
<b>Basic Biological Studies</b>				
Gene knockout	ESCs	<i>Mettl3</i> erase m6A modification leading to cell differentiation	2014	13
	ESCs	p53/63/73 knockout causes mesendodermal differentiation	2017	14
Control expression	ESCs	downregulation of Oct4 leads to lineage differentiation	2014	18
	iPSCs	Dox-inducible CRISPRi represses gene expression	2016	19
	PSCs	Dox-inducible CRISPRa activates gene expression	2017	20
	NSCs	inhibition of miR-199a/214 increases tumor tropism	2016	23
Genome scale screening	ESCs	identification of essential genes for cell survival by knockout of 18,080 genes simultaneously	2014	28
	iPSCs	identification of 326 functional loci of lncRNAs	2017	29
Gene knockin	iPSCs	generation of collagen-GFP reporter for cell sorting	2016	35
	ESCs	monitor pharmacological profiles of striatal cultures using DARPP-32-GFP reporter cell	2017	36
<b>Clinical Translational Studies</b>				
Disease model and drug screening	ESCs	<i>RB1</i> -null cells showed aberrant mitochondria and were sensitive to carboplatin (retinoblastoma)	2017	40
	iPSCs	isogenic iPSCs model for pathomechanism and drug screening (myelodysplastic syndrome)	2016	42
	iPSCs	point mutation iPSCs model for studying individual difference in hypoglycemia	2017	43
	ESCs	WRN-null hESCs model Werner syndrome (WS-iPSCs showed abnormal karyotypes seriously)	2015	44
	organoids	gene knockout kidney organoids showed cyst of tubules	2015	45
	organoids	modeling dyskeratosis congenita reveals the therapeutic functions of Wnt agonists	2016	49
	organoids	gene knockout intestinal organoids form tumors in mice kidney after subcapsule injection	2015	51
	organoids	organoids model reveals the function of <i>APC</i> and <i>P53</i> in intestinal neoplasia	2015	52
	organoids	organoids model reveals the function of TGF- $\beta$ in colorectal cancer (CRC) formation	2016	53
	organoids	combinatorial drug responses in organoids model (colorectal cancer [CRC])	2016	54
Gene correction therapy	HSCs	gene-corrected patient HSCs showed functional recovery in X-linked chronic granulomatous	2017	65
	iPSCs	gene-corrected patient iPSCs recovered $\beta$ -globin (HBB) expression	2015	59
	organoids	gene-corrected patient organoids showed functional recovery in cystic fibrosis	2013	50
	HSCs	gene-corrected patient HSCs recovered $\beta$ -globin (HBB) expression in $\beta$ -thalassemia	2016	61
	iPSCs	gene-corrected patient iPSCs showed functional recovery in hemophilia A	2015	63
	iPSCs	gene-corrected patient iPSCs showed normal phenotypes in Huntington's disease	2017	64
Anti-virus therapy	T cells	CXCR4-disrupted T cells showed HIV resistance	2015	69
	HSCs	CCR5-disrupted HSCs presented HIV resistance	2017	70
	iPSCs	CCR5-disrupted iPSCs and its derived blood cells showed HIV resistance	2015	71
	iPSCs	CCR5 $\Delta$ 32 iPSCs and its derived cells showed HIV resistance	2014	72
	iPSCs	CRISPR/Cas9-expressed iPSCs showed HIV resistance by elimination of virus RNA	2015	74
Anti-tumor therapy	CAR T cells	the anti-tumor efficacy of CAR T cells was enhanced through disrupting the PD-1 gene	2017	77
	CAR T cells	the anti-tumor efficacy of CAR T cells was improved by fusing CD19 CAR to the TRAC gene	2017	78
	iPSCs	NK cells derived from ADAM17-disrupted iPSCs presented higher HIV resistance	2016	79

hESCs, human embryonic stem cells.

carboplatin.<sup>40</sup> Moreover, the isogenic human PSC knockout disease model is crucial to eliminate the individual variations and unknown gene mutations that occur during iPSC reprogramming.<sup>41</sup> Chang et al.<sup>42</sup> demonstrated different drug responses among cells derived from different patient-specific iPSCs and CRISPR/Cas9-generated isogenic PSCs. Employing CRISPR/Cas9 can precisely introduce mutations (point mutation, insertion, or deletion) into human PSCs to

generate gene mutant PSCs and provide a patient disease model. It bypasses the limitations of iPSC generation that requires biopsy or reprogramming, and provides a strategy to determine precisely why different patients with the same mutations present with different features during pathogenesis. Guo et al.<sup>43</sup> used CRISPR/Cas9 to induce a point mutation (c.1288G>T) in the *Men1* gene of normal iPSCs to study the effect of individual differences in hypoglycemia.



A CRISPR/cas9-mediated human PSC disease model can be applied when use of patient-specific iPSCs is not appropriate or possible. For example, Zhang et al.<sup>44</sup> used WRN null human ESCs to model Werner syndrome because patient-specific iPSCs showed abnormal karyotypes. Taken together, CRISPR/cas9 technologies employed in human PSCs can provide an array of genetically defective human disease models.<sup>41,45</sup> Nonetheless, it is important to bear in mind that PSC-derived somatic cells are young cells that more closely resemble fetal cells.

**Human SSCs.** CRISPR/Cas9 can be used to manipulate human SSCs including hematopoietic stem cells (HSCs), NSCs, and mesenchymal stem cells (MSCs).<sup>46–48</sup> The challenge lies in obtaining a sufficient number of pure cells for disease modeling and drug screening if these SSCs are difficult to maintain or expand from a relatively small number of cells. Use of the CRISPR/cas9 system has enabled many genes in HSCs to be successfully manipulated.<sup>46</sup> Unfortunately, difficulties persist in the maintenance of these gene-manipulated HSCs during selection, purification, and expansion. These limitations restrict the application of CRISPR/Cas9 in disease modeling and drug screening.

**Organoids.** Human organoids are 3D cultures derived from human PSCs, SSCs, or primary tissues. They have the ability of self-renewal and can self-organize to be primary tissue-like clumps that contain several kinds of cells. Hence they are regarded as better sources for biomedical research than 2D human cell cultures. PSC-derived organoids have been utilized to model human genetic disease and screen drugs with the assistance of CRISPR/Cas9-mediated gene manipulation. Basically, gene mutations are introduced into PSCs using CRISPR/Cas9; then the engineered PSCs become gene mutant organoids under 3D culturing conditions and can be used in disease modeling and drug screening. Freedman et al.<sup>45</sup> generated gene mutant kidney organoids from knockout podocalyxin, *PKD1* or *PKD2* genes of human ESCs using CRISPR/Cas9, which showed abnormal features (junctional organization defects of podocyte-like cells or cyst of kidney tubules). The *DKC1* gene mutation causes congenital dyskeratosis. Woo et al.<sup>49</sup> generated intestinal organoids from patient-specific iPSCs, both isogenic and gene-corrected organoids, to reveal a feedback loop between the Wnt pathway and telomere function. This also demonstrated the therapeutic action of Wnt agonists in the treatment of congenital dyskeratosis.<sup>49</sup> In addition, CRISPR/Cas9 can be utilized to directly mediate gene manipulation in SSCs or primary tissue-derived organoids. Their pluripotency can be sustained well under 3D culture conditions when screening the targeted colonies.<sup>50</sup> This strategy has been proposed as a new platform for cancer research. Matano et al.<sup>51</sup> engineered normal human intestinal organoids by knocking out several tumor suppressor genes and oncogenes simultaneously, and showed formation of tumors following subcapsular injection into the kidney. Similarly, Drost et al.<sup>52</sup> produced the most common mutant genes in intestinal organoids to reveal the functions of *APC* and *P53* genes in intestinal neoplasia. Fessler et al.<sup>53</sup> generated *BRAF*<sup>V600E</sup> mutant organoids to explore the function of transforming growth factor  $\beta$  (TGF- $\beta$ ) in

transforming sessile serrated adenomas (SSAs) into colorectal cancer (CRC). SSCs or primary tissue-derived organoids can also be utilized to screen anti-tumor drugs following the introduction of gene mutations by CRISPR/Cas9. Verissimo et al.<sup>54</sup> tested the combinatorial drug response for treating CRC using *RAS* and *KRAS* gene mutant normal and tumor organoids.

### Stem Cell Therapy

DSB introduced by CRISPR/Cas9 significantly promotes HDR in targeted cells. Original stem cells can be easily remolded using these genetic engineering techniques to generate new function-modified stem cells for cell therapy. There is no doubt that CRISPR/Cas9 has significantly broadened the application of stem cells in human regenerative medicine.

**Gene Correction Therapy.** Many gene mutations at the genome level often result in genetic disorders. Although allografts have been widely utilized in preclinical experiments and clinical cell therapy studies, immune rejection remains a concern.<sup>55,56</sup> CRISPR/Cas9-mediated gene correction provides a new vision of cell therapy for many human genetic diseases. The general strategy is to break the genomic DNA near the targeted genes using CRISPR/Cas9 and simultaneously provide a donor that presents normal sequences. The mutant gene fragments can be corrected through homologous recombination, and the associated functional defect in the targeted cells is corrected. It has been demonstrated in an animal model that gene correction offers a definitive cure for genetic disease. Li's group<sup>57</sup> co-injected gRNA, Cas9 nuclease, and healthy donor plasmid of the *Crygc* gene into the zygotes of cataract mice and generated cataract-free mice. Patient-specific iPSCs are the most common source for gene correction because they can be differentiated into all kinds of functional somatic cells after gene correction. Gene-corrected  $\beta$ -thalassemia patient-specific iPSCs are able to restore HBB expression and be differentiated into functional hematopoietic progenitor cells.<sup>58,59</sup> Patient-specific organoids offer a promising source for gene correction and are more easily differentiated into somatic cells for transplantation compared with PSPs. Schwank et al.<sup>50</sup> successfully obtained function recovered cells after they repaired the mutant CFTR gene in human intestinal stem cell organoids. For therapeutic purposes, stem cells should be maintained in a "stemness" state. Hence we normally do not criticize the purity of manipulated cells, and use adeno-associated virus (AAV) to deliver the donor for gene correction. Porteus's group<sup>60,61</sup> finally obtained around 38% biallelic-corrected  $\beta$ -thalassemia HSCs using AAV-assisted gene correction after rough purification. This was sufficient for cell transplantation and avoided the difficulties caused by random integration in lentivirus or retrovirus-mediated gene therapy.<sup>60,61</sup> CRISPR/Cas9-mediated gene correction has become a principal therapeutic strategy in the study of genetic diseases such as  $\beta$ -thalassemia, Duchenne muscular dystrophy, hemophilia A, Huntington's disease, and X-linked chronic granulomatous disease.<sup>58,62–65</sup> It should nonetheless be noted that although we can obtain functionally recovered stem cells after gene correction in vitro, their therapeutic safety and efficacy after transplantation remain to be evaluated.



**Anti-virus Therapy.** Some viruses bind to the surface receptors of host cells during infection. As mentioned above, CRISPR/Cas9 can help modify the targeted cells efficiently and easily. Hence infection with HIV can be prevented by modifying the receptors of human cells. For example, CCR5 and CXCR4 are co-receptors of human white blood cells for HIV infection.<sup>66,67</sup> There are reports showing that CCR5- or CXCR4-disrupted human CD4<sup>+</sup> T cells, HSCs or iPSCs, present HIV resistance after CRISPR/Cas9-mediated gene modification.<sup>68–71</sup> Nevertheless, cells acquired HIV resistance through direct gene disruption, and some basic functions may also have been affected. It may be advisable to first define some natural mutations that do not affect the host's biological functions before utilizing CRISPR/Cas9 to introduce desirable mutations (e.g., point mutation) in cell engineering. Ye et al.<sup>72</sup> introduced a natural mutation (CCR5Δ32) into normal human iPSCs and finally obtained HIV-resistant monocytes and macrophages after cell differentiation. In addition, CRISPR/Cas9 has been demonstrated to be effective in targeting the genetic material of viruses.<sup>73</sup> Liao et al.<sup>74</sup> engineered human iPSCs to express HIV-targeted gRNA and Cas9 protein that could protect cells from virus infection by disrupting the RNA of HIV in iPSCs and their derived adult cells.

**Anti-tumor Therapy.** Genetically engineered human immune cells and stem cells have already been widely used in anti-tumor research, such as delivering anti-tumor proteins and inducing cancer cell death.<sup>75</sup> Chimeric antigen receptor (CAR) T cells are considered a milestone in the cure of refractory blood cancer.<sup>76</sup> CRISPR/Cas9 can be used to increase their anti-tumor efficacy by disrupting the programmed death protein 1 (PD-1) in CAR T cells by eliminating PD-L1 (PD-1 ligand) expressed tumor xenografts in vivo.<sup>77</sup> In addition, CRISPR/Cas9 can be utilized to eliminate the risks associated with lentivirus-mediated CAR T cells, such as the potential of oncogenesis and recovery of replication. Eyquem et al.<sup>78</sup> engineered T cells to express CAR uniformly by directly fusing CD19 CAR to cells' TRAC gene and also increased their potency. For the treatment of solid tumors, Blum et al.<sup>79</sup> introduced the stable expression of CD16a (S197P) and disrupted ADAM17 in human iPSCs that could further differentiate into natural killer cells for anti-tumor therapeutic research.

## Challenges

### Off-Target

A common problem of all gene manipulation techniques, including CRISPR/Cas9 systems, is that they miss their target. The mismatch between gRNA and genomic DNA is the main cause of non-specificity in genome editing. It has been shown that Cas9 nuclease has diverse tolerance to the mismatch between gRNA and targeted genomic DNA. The PAM mismatch (e.g., RNG) can also lead to being off-target.<sup>80,81</sup> The ratio of being off-target is relative to the targeted genes and hosts. For example, CRISPR/Cas9 can generate off-targets at a different ratio for different genes (60% for *HBB* gene and 22% for *CCR5* gene) in the HEK293 cell line, while the ratio of off-targets is just 0.34% for the *RNF2* gene in the HeLa cell line.<sup>82,83</sup> Off-targets can also be identified in stem cells. Wu et al.<sup>84</sup> revealed that off-target

sites were mainly related to genes in mouse ESCs. Fortunately, recent whole-genome sequencing results have indicated that the incidence of off-targets caused by CRISPR/Cas9 is very low in human stem cells.<sup>85–87</sup> Although some inaccuracy is inevitable, it can be controlled or reduced using several common strategies.

**Optimize gRNA Design.** Well-designed gRNAs play very critical roles in ensuring a high efficiency of genome cleavage and low incidence of off-targets in human stem cell research. There are various online tools for gRNA design that are user-friendly.<sup>88–94</sup> When sequences of targeted genes are uploaded, all gRNAs that contain PAM (NGG) will be generated automatically, and the possibility of being off-targets is evaluated. Under normal circumstances, a higher score means a lower possibility. Therefore, the gRNAs with high scores are recommended in order to reduce the number of off-targets. Nevertheless, deep sequencing or nuclease detection is required to examine the incidence of off-targets in stem cells. Some studies have shown that shorter gRNAs can reduce the occurrence of off-target by reducing their mispairing with the targeted genome, but the indels of on-target will also decrease accordingly, because binding of shorter gRNAs to the targeted genome is not as stable as that of longer ones.<sup>82,83</sup>

**Modify Cas9 Nuclease or gRNA.** Cas9 nickase (Cas9n) is a mutant version of Cas9 that generates just a nick on the gRNA-bound strand without breaking the whole double-strand DNA.<sup>95</sup> This system needs a pair of gRNAs to form two gRNA/Cas9n complexes for DNA cleavage and can dramatically decrease the off-target in human ESCs.<sup>96</sup> Kleinstiver et al.<sup>97,98</sup> modified the traditional *Streptococcus pyogenes* Cas9 (SpCas9) to identify other PAM sequences or improve fidelity. Fu et al.<sup>99</sup> reduced off-targets 5,000-fold by using truncated gRNAs.

**Exploit Alternatives to Classic SpCas9.** Type I and type III CRISPR-Cas immune systems share a similar mechanism to type II. Tsai et al.<sup>100</sup> utilized a dimeric RNA to guide the highly specific cleavage of FokI nucleases based on the classic CRISPR/Cas9 system. Cas3 and Cmr are nucleases of the type I and type III CRISPR-Cas immune system and show better specificity than Cas9.<sup>101,102</sup> More encouragingly, no off-target has been detected using the CRISPR/Cpf1 system.<sup>103,104</sup>

### Editing Efficiency

Editing efficiency is another important aspect of gene manipulation techniques. CRISPR/Cas9 has been widely utilized and has shown high genome-editing efficiency in various mammalian cells.<sup>105</sup> In addition, the high editing efficiency can significantly reduce costs when processing stem cells in vitro. Nonetheless, its genome-editing efficiency is insufficient for human stem cell research and hampers the transfer of genome editing from the bench to the bedside. For example, a virus is commonly used for CRISPR/Cas9 delivery, but this confers risks for the clinical transplantation of stem cells. It is almost impossible for some stem cells, such as HSCs and MSCs, to be expanded sufficiently for clinical application from screening a single cell after the manipulation of CRISPR/Cas9.



**Optimize the Expression of gRNA/Cas9.** Cas9-induced genome editing is related to gRNA expression and gRNA/Cas9 binding.<sup>106</sup> Employing purified gRNA and Cas9 protein has been shown to directly improve the genome-editing efficiency in human stem cells and provide more stable and sufficient Cas9 nuclease for genome editing. Kim et al.<sup>107</sup> delivered purified gRNA and Cas9 into human H9 ESCs, and finally achieved 23% indels, which was almost five times higher than that reported by Mali et al.<sup>8</sup> in 2013. Gundry et al.<sup>108</sup> remarkably enhanced the genome-editing efficiency of CRISPR/Cas9 in human HSCs using purified gRNA and Cas9 nuclease. This avoids the effect of protein transcription and translation. In addition, editing efficiency can be improved by controlling the delivery time of gRNA and Cas9 nuclease in 293 cells, and may also be appropriate for stem cells.<sup>109</sup>

**Modify gRNAs or Cas9 Nucleases Artificially.** Longer gRNA binds to Cas9 nuclease more tightly with a consequent huge improvement in genome-editing efficiency.<sup>105</sup> Exogenous RNAs cannot stay long in human cells because of RNA degeneration.<sup>110</sup> Genome-editing efficiency can be improved if gRNA can be maintained for a longer time prior to degradation. Hendel et al.<sup>111</sup> utilized some chemical groups to protect the phosphoramidites of gRNAs and significantly enhanced the genome-editing efficiency of CRISPR/Cas9 in T cells and CD34<sup>+</sup> HSCs. Other artificially modified Cas9 nuclease or alternatives to CRISPR/Cas9 have also been reported to have greater genome-editing efficiency, such as Cas3-CRISPR, type III-A CRISPR-Cas-Csm, FokI-CRISPR, and Cpf1-CRISPR.<sup>100–102,104</sup> Nonetheless, stronger experimental evidence is required to support these alternatives in stem cell studies.

**Preprocess Host Cells.** CRISPR/Cas9-mediated genome editing depends on NHEJ and HDR. Yu et al.<sup>112</sup> identified two compounds (L755507 and brefeldin A) that improved genome-editing efficiency by enhancing HDR efficiency in human PSCs. SCR7 is a small molecular inhibitor of the NHEJ pathway.<sup>113</sup> Zygotes treated with SCR7 showed a 19-fold improvement in gene knockin efficiency using CRISPR/Cas9.<sup>114</sup> Similarly, RS-1, an HDR enhancer, improved the gene knockin efficiency 2- to 5-fold in mouse embryos.<sup>115</sup> Other bioactive proteins, such as E1B55K and E4orf6, can likewise increase the knockin efficiency.<sup>116</sup> Although the toxicity of these small molecules and proteins requires extensive evaluation in human stem cells, they provide invaluable information to improve the editing efficiency of CRISPR/Cas9 in stem cell research.

**Utilize Auxiliary Elements.** Microhomology-mediated end joining (MMEJ) is another DNA repairing system in cells.<sup>117</sup> On this basis, a precise integration into a target chromosome (PITCh) system has been designed to improve the integration efficiency of gene knockin using several gRNAs to cut genome and PITCh vectors.<sup>118</sup> It is easier during donor construction, because the PITCh vector needs only a short micro homologous arm (5–25 bp) that can be synthesized directly. In contrast, classical homologous arms normally comprise thousands of base pairs of DNA amplified by PCR. Nonetheless, more experimental evidence is required to support its use in human stem cells. *PiggyBac* is a transposon system that can achieve change

in position and insertion and deletion of DNA fragments from a chromosome.<sup>119</sup> It has been reported to dramatically increase CRISPR/Cas9-mediated genome-editing efficiency in human PSCs from the normal level of 1%–5% without using an integrated screening cassette.<sup>58,120</sup> Nonetheless, the random transposable action of *PiggyBac* transposons needs to be evaluated.

### Delivery Routes

The commercial CRISPR/Cas9 genome-editing system is generally presented as plasmids, RNAs, or proteins. Nonetheless, this system cannot be used for gene manipulation unless they can be delivered into the targeted hosts. Selection of an appropriate delivery method is thus vital for CRISPR/Cas9-mediated gene manipulations. Normally, they have delivery strategies similar to other gene-manipulating tools such as RNAi, ZFN, or TALEN. Nonetheless, because of the unique features of human PSCs and SSCs in regenerative medicine, different delivery strategies need to be considered carefully.

**Transient Expression Strategies.** Gene manipulation can be easily achieved by transient transfections of gRNA/Cas9 nuclease-expressed plasmids or their purified synthetic products in common cells.<sup>7,8,107,121</sup> The situation becomes more complex in stem cell studies as stem cells are more fragile, sensitive, or resistant to the transient delivery methods than common somatic cells and immortalized cell lines. Hence appropriate delivery methods are required. In terms of efficiency of delivery, micro-injection achieves the highest up to 100% for direct injection of substrates into targeted cells one by one through glass micro-pipettes.<sup>122</sup> But this micro-injection cannot be applied for large-scale injections, and thus limits its application to immortalized cells (e.g., PSCs).<sup>123</sup> Both electrotransfection and nucleofection have achieved high transfection efficiency in various human stem cells. The former can treat more kinds of cells in principle, while the latter presents higher cell viability after transfection.<sup>58,124–126</sup> Millions of cells can be handled in one reaction based on electroporation; nonetheless, much time and effort have been expended in purifying the real transfected cells using selection cassettes.<sup>58,124</sup> Lipidosome reagents are not as popular as the other three methods for human stem cell transfection, because their transfection efficiency is poor when targeting many human stem cell lines. In addition, many human stem cell lines are extremely sensitive to the cytotoxicity of transfection reagents and the mechanical damage that occurs during cell pretreatments. Some new lipidosome-like delivery methods are now available with CRISPR/Cas9. Yin et al.<sup>127</sup> exploited a new lipid nano-particle to deliver Cas9 mRNA for genome editing; Jiang et al.<sup>128</sup> optimized the formula using lipid-like nano-particles (LLNs) for gRNA and Cas9 mRNA delivery. It has been noted that some stem cell lines are sensitive and hard to be transfected.<sup>50</sup>

**Lentivirus-Mediated Strategy.** Lentivirus is another commonly used vehicle for CRISPR/Cas9 delivery. It is more stable, more efficient, and can theoretically infect almost all kinds of human stem cells in vivo and in vitro with high efficiency and low cellular toxicity.<sup>37,129,130</sup> It presents several remarkable advantages for stem



cell studies compared with transient strategies. First, lentivirus can introduce high, stable, and permanent expression of exogenous genes for random genome integration, which is crucial for CRISPR imaging and CRISPR screening when infecting human stem cells such as human PSCs, SSCs, or organoids.<sup>18,29,37,38,131</sup> Second, CRISPR-mediated genetic screening needs lentivirus to deliver thousands of gRNAs into stem cells with high efficiency and low cellular toxicity.<sup>25,132</sup> Third, lentivirus is directly added for co-culturing with cells and eliminates the damage from cell pretreatment. Nonetheless, the random genome integration remains an inevitable barrier that limits clinical applications of lentivirus. Although lentivirus has been proven to be an effective delivery vehicle to mediate genome editing in stem cells, it is still not recommended for single or multiple gene manipulations.<sup>133,134</sup> Uncontrolled gene mutations introduced by random integrations are not desired, while integrase-defective lentivirus shows a lower infection efficiency and gene expression level than the normal lentivirus.<sup>135</sup>

**AAV-Mediated Strategy.** Theoretically, AAV supports all applications of the CRISPR/Cas9 gene manipulating system similar to lentivirus (e.g., genome editing, CRISPRi/a, CRISPR imaging, and so on) because it shares the advantages of lentivirus in stem cell research.<sup>136,137</sup> We can easily obtain extremely high titering AAV virus using helper plasmids during virus packaging with consequent higher infection efficiency than lentivirus.<sup>138,139</sup> More importantly, an AAV-delivered donor is genome integration-free. It permanently exists as episomal DNA in cells and largely promotes efficiency of CRISPR/Cas9-mediated gene correction in stem cell therapy.<sup>140–142</sup> For example, Tabebordbar et al.<sup>143</sup> repaired mutant *Dmd* genes by AAV-delivered CRISPR/Cas9 in muscle stem cells. Unfortunately, the insert size capacity of AAV was far smaller than lentivirus. With the exception of SaCas9 (*Staphylococcus aureus*), smaller nucleases need to be exploited to enhance editing efficiency when choosing AAV as the delivery vehicle.<sup>144</sup> In addition, AAV-delivered gRNA and Cas9 nuclease will be permanently expressed in all new divided cells. This may induce undesired genome damage and ultimately lead to cell death.<sup>145</sup> Although this situation has been resolved by delivering donor (AAV) and CRISPR/Cas9 (transient delivery strategies) separately, the advantages of AAV are partly concealed.<sup>61</sup> In addition, the immunogenicity of AAV remains another risk that must be considered.<sup>146</sup>

**Novel Delivery Strategies.** With the development of CRISPR/Cas9, some novel delivery methods have emerged that eliminate the toxic effects or safety problems associated with transient transfection or virus infections. A chip containing micro-constrictions can generate transient membrane holes on cells by mechanical deformation to deliver CRISPR/Cas9 plasmids when the mixture of cells and plasmid pass the chip rapidly.<sup>147</sup> This method is reported to introduce high efficiency in genome editing with low cell loss in hard-to-transfect cells.<sup>147</sup> Based on the membrane punching mechanism, it also has the advantages and disadvantages of electroporation. The other methods are to utilize cell-penetrating peptides (CPP) to conjugate gRNA and Cas9 nuclease for CRISPR/Cas9 delivery in a plasmid-

free, transfecting reagent-free, and virus-free manner.<sup>121</sup> A disadvantage is its relatively low transfection efficiency.

### Prospects

Since its introduction in 2013, the CRISPR/Cas9 genome-editing system has been rapidly developed and widely used in all human stem cell studies. All gene-manipulating capacities (e.g., knockout, knockin, knockdown, and expression activating) are incredibly integrated in one technique. It is user-friendly, efficacious, and economical such that genome manipulation ceases to be a challenge for new researchers. Undoubtedly, the CRISPR/Cas9 genome-editing system has revolutionarily changed the fundamental and translational stem cell research. Although solutions are still required to reduce the off-target effect, improve editing efficiency, and exploit novel delivery strategies at a low cost and with high safety for clinical stem cell studies, CRISPR/Cas9-mediated preclinical studies have made remarkable progress and offer huge potential in human stem cell and regenerative research.

### AUTHOR CONTRIBUTIONS

Conceptualization, Z.Z. and Q.L.; Writing – Original Draft, Z.Z. and Q.L.; Writing – Review & Editing, Z.Z., Y.Z., F.G., S.H., and Q.L.; Supervision, K.S.C. and Q.L.; Funding Acquisition, K.S.C., H.-F.T., and Q.L.

### CONFLICTS OF INTEREST

The authors declare that they have no competing interests.

### ACKNOWLEDGMENTS

This research was supported in part by the NSFC (grants 31270967 and 31571407 to Q.L.), a Shenzhen seed grant (JCYJ20140828163633995), Hong Kong TRS (grant T12-708/12-N), and Hong Kong RGC GRF (grants HKU17113816 and HKU17120517 to Q.L.).

### REFERENCES

- Mojica, F.J., Díez-Villaseñor, C., Soria, E., and Juez, G. (2000). Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria. *Mol. Microbiol.* 36, 244–246.
- van der Oost, J., Westra, E.R., Jackson, R.N., and Wiedenheft, B. (2014). Unravelling the structural and mechanistic basis of CRISPR-Cas systems. *Nat. Rev. Microbiol.* 12, 479–492.
- Kunin, V., Sorek, R., and Hugenoltz, P. (2007). Evolutionary conservation of sequence and secondary structures in CRISPR repeats. *Genome Biol.* 8, R61.
- Haft, D.H., Selengut, J., Mongodin, E.F., and Nelson, K.E. (2005). A guild of 45 CRISPR-associated (Cas) protein families and multiple CRISPR/Cas subtypes exist in prokaryotic genomes. *PLoS Comput. Biol.* 1, e60.
- Makarova, K.S., Haft, D.H., Barrangou, R., Brouns, S.J., Charpentier, E., Horvath, P., Moineau, S., Mojica, F.J., Wolf, Y.I., Yakunin, A.F., et al. (2011). Evolution and classification of the CRISPR-Cas systems. *Nat. Rev. Microbiol.* 9, 467–477.
- Mojica, F.J., Díez-Villaseñor, C., García-Martínez, J., and Almendros, C. (2009). Short motif sequences determine the targets of the prokaryotic CRISPR defence system. *Microbiology* 155, 733–740.
- Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, L.A., and Zhang, F. (2013). Multiplex genome engineering using CRISPR/Cas systems. *Science* 339, 819–823.
- Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, J.E., Norville, J.E., and Church, G.M. (2013). RNA-guided human genome engineering via Cas9. *Science* 339, 823–826.





9. Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., and Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. *Nat. Protoc.* 8, 2281–2308.
10. Ding, Q., Regan, S.N., Xia, Y., Ostrom, L.A., Cowan, C.A., and Musunuru, K. (2013). Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. *Cell Stem Cell* 12, 393–394.
11. Wang, H., La Russa, M., and Qi, L.S. (2016). CRISPR/Cas9 in genome editing and beyond. *Annu. Rev. Biochem.* 85, 227–264.
12. Trounson, A., and McDonald, C. (2015). Stem cell therapies in clinical trials: progress and challenges. *Cell Stem Cell* 17, 11–22.
13. Batista, P.J., Molinie, B., Wang, J., Qu, K., Zhang, J., Li, L., Bouley, D.M., Lujan, E., Haddad, B., Daneshvar, K., et al. (2014). m(6)A RNA modification controls cell fate transition in mammalian embryonic stem cells. *Cell Stem Cell* 15, 707–719.
14. Wang, Q., Zou, Y., Nowotshin, S., Kim, S.Y., Li, Q.V., Soh, C.L., Su, J., Zhang, C., Shu, W., Xi, Q., et al. (2017). The p53 family coordinates Wnt and Nodal inputs in mesendodermal differentiation of embryonic stem cells. *Cell Stem Cell* 20, 70–86.
15. Chen, Y., Cao, J., Xiong, M., Petersen, A.J., Dong, Y., Tao, Y., Huang, C.T., Du, Z., and Zhang, S.C. (2015). Engineering human stem cell lines with inducible gene knockout using CRISPR/Cas9. *Cell Stem Cell* 17, 233–244.
16. Cao, J., Wu, L., Zhang, S.M., Lu, M., Cheung, W.K., Cai, W., Gale, M., Xu, Q., and Yan, Q. (2016). An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting. *Nucleic Acids Res.* 44, e149.
17. Qi, L.S., Larson, M.H., Gilbert, L.A., Doudna, J.A., Weissman, J.S., Arkin, A.P., and Lim, W.A. (2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell* 152, 1173–1183.
18. Kearns, N.A., Genga, R.M., Enuameh, M.S., Garber, M., Wolfé, S.A., and Maehr, R. (2014). Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells. *Development* 141, 219–223.
19. Mandegar, M.A., Huebsch, N., Frolov, E.B., Shin, E., Truong, A., Olvera, M.P., Chan, A.H., Miyaoka, Y., Holmes, K., Spencer, C.L., et al. (2016). CRISPR interference efficiently induces specific and reversible gene silencing in human iPSCs. *Cell Stem Cell* 18, 541–553.
20. Guo, J., Ma, D., Huang, R., Ming, J., Ye, M., Kee, K., Xie, Z., and Na, J. (2017). An inducible CRISPR-ON system for controllable gene activation in human pluripotent stem cells. *Protein Cell* 8, 379–393.
21. Larson, M.H., Gilbert, L.A., Wang, X., Lim, W.A., Weissman, J.S., and Qi, L.S. (2013). CRISPR interference (CRISPRi) for sequence-specific control of gene expression. *Nat. Protoc.* 8, 2180–2196.
22. Liu, S.J., Nowakowski, T.J., Pollen, A.A., Lui, J.H., Horlbeck, M.A., Attenello, F.J., He, D., Weissman, J.S., Kriegstein, A.R., Diaz, A.A., and Lim, D.A. (2016). Single-cell analysis of long non-coding RNAs in the developing human neocortex. *Genome Biol.* 17, 67.
23. Luo, Y., Xu, X., An, X., Sun, X., Wang, S., and Zhu, D. (2016). Targeted inhibition of the miR-199a/214 cluster by CRISPR interference augments the tumor tropism of human induced pluripotent stem cell-derived neural stem cells under hypoxic condition. *Stem Cells Int.* 2016, 3598542.
24. Pan, A., Weintraub, N.L., and Tang, Y. (2014). Enhancing stem cell survival in an ischemic heart by CRISPR-dCas9-based gene regulation. *Med. Hypotheses* 83, 702–705.
25. Wang, T., Wei, J.J., Sabatini, D.M., and Lander, E.S. (2014). Genetic screens in human cells using the CRISPR-Cas9 system. *Science* 343, 80–84.
26. Zhou, Y., Zhu, S., Cai, C., Yuan, P., Li, C., Huang, Y., and Wei, W. (2014). High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. *Nature* 509, 487–491.
27. Morgens, D.W., Deans, R.M., Li, A., and Bassik, M.C. (2016). Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes. *Nat. Biotechnol.* 34, 634–636.
28. Shalem, O., Sanjana, N.E., Hartenian, E., Shi, X., Scott, D.A., Mikkelsen, T., Heckl, D., Ebert, B.L., Root, D.E., Doench, J.G., and Zhang, F. (2014). Genome-scale CRISPR-Cas9 knockout screening in human cells. *Science* 343, 84–87.
29. Liu, S.J., Horlbeck, M.A., Cho, S.W., Birk, H.S., Malatesta, M., He, D., Attenello, F.J., Villalta, J.E., Cho, M.Y., Chen, Y., et al. (2017). CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells. *Science* 355, eaah7111.
30. Parnas, O., Jovanovic, M., Eisenhaure, T.M., Herbst, R.H., Dixit, A., Ye, C.J., Przybylski, D., Platt, R.J., Tirosh, I., Sanjana, N.E., et al. (2015). A genome-wide CRISPR screen in primary immune cells to dissect regulatory networks. *Cell* 162, 675–686.
31. Yang, H., Wang, H., Shivalila, C.S., Cheng, A.W., Shi, L., and Jaenisch, R. (2013). One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. *Cell* 154, 1370–1379.
32. Auer, T.O., Durooure, K., De Cian, A., Concordet, J.P., and Del Bene, F. (2014). Highly efficient CRISPR/Cas9-mediated knock-in in zebrafish by homology-independent DNA repair. *Genome Res.* 24, 142–153.
33. Pierce, A.J., Johnson, R.D., Thompson, L.H., and Jasin, M. (1999). XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. *Genes Dev.* 13, 2633–2638.
34. Liang, F., Han, M., Romanienko, P.J., and Jasin, M. (1998). Homology-directed repair is a major double-strand break repair pathway in mammalian cells. *Proc. Natl. Acad. Sci. USA* 95, 5172–5177.
35. Adkar, S.S., Willard, V.P., Brunger, J.M., Shiao, K.T., Gersbach, C.A., and Guilak, F. (2016). Targeted genome editing of human induced pluripotent stem cells using CRISPR/CAS9 to generate a knock-in type II collagen reporter for the purification of chondrogenic cells. *Mol. Ther.* 24 (Suppl 1), S128.
36. Hunt, C.P.J., Pouton, C.W., and Haynes, J.M. (2017). Characterising the developmental profile of human embryonic stem cell-derived medium spiny neuron progenitors and assessing mature neuron function using a CRISPR-generated human DARPP-32(WT/eGFP-AMP) reporter line. *Neurochem. Int.* 106, 3–13.
37. Chen, B., Gilbert, L.A., Cimini, B.A., Schnitzbauer, J., Zhang, W., Li, G.-W., Park, J., Blackburn, E.H., Weissman, J.S., Qi, L.S., and Huang, B. (2013). Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. *Cell* 155, 1479–1491.
38. Anton, T., Bultmann, S., Leonhardt, H., and Markaki, Y. (2014). Visualization of specific DNA sequences in living mouse embryonic stem cells with a programmable fluorescent CRISPR/Cas system. *Nucleus* 5, 163–172.
39. Classon, M., and Harlow, E. (2002). The retinoblastoma tumour suppressor in development and cancer. *Nat. Rev. Cancer* 2, 910–917.
40. Avior, Y., Lezmi, E., Yanuka, D., and Benvenisty, N. (2017). Modeling developmental and tumorigenic aspects of trilateral retinoblastoma via human embryonic stem cells. *Stem Cell Reports* 8, 1354–1365.
41. Sternecker, J.L., Reinhardt, P., and Schöler, H.R. (2014). Investigating human disease using stem cell models. *Nat. Rev. Genet.* 15, 625–639.
42. Chang, C.-J., Kotini, A., Teruya-Feldstein, J., Abdel-Wahab, O., Bradley, R., and Papapetrou, E.P. (2016). Isogenic iPSC models of SRSF2-mutant myelodysplastic syndrome capture disease phenotypes, splicing defects and drug responses. *Blood* 128, 962.
43. Guo, D., Liu, H., Gao, G., Liu, Y., Zhuang, Y., Yang, F., Wang, K., Zhou, T., Qin, D., Hong, L., et al. (2017). Creating a patient carried Men1 gene point mutation on wild type iPSCs locus mediated by CRISPR/Cas9 and ssODN. *Stem Cell Res. (Amst.)* 18, 67–69.
44. Zhang, W., Li, J., Suzuki, K., Qu, J., Wang, P., Zhou, J., Liu, X., Ren, R., Xu, X., Ocampo, A., et al. (2015). Aging stem cells. A Werner syndrome stem cell model unveils heterochromatin alterations as a driver of human aging. *Science* 348, 1160–1163.
45. Freedman, B.S., Brooks, C.R., Lam, A.Q., Fu, H., Morizane, R., Agrawal, V., Saad, A.F., Li, M.K., Hughes, M.R., Werff, R.V., et al. (2015). Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids. *Nat. Commun.* 6, 8715.
46. Mandal, P.K., Ferreira, L.M., Collins, R., Meissner, T.B., Boutwell, C.L., Friesen, M., Vrbanac, V., Garrison, B.S., Stortchevoi, A., Bryder, D., et al. (2014). Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. *Cell Stem Cell* 15, 643–652.
47. Bressan, R.B., Dewari, P.S., Kalantzaki, M., Gangoso, E., Matjusaitis, M., Garcia-Diaz, C., Blin, C., Grant, V., Bulstrode, H., Gogolok, S., et al. (2017). Efficient



- CRISPR/Cas9-assisted gene targeting enables rapid and precise genetic manipulation of mammalian neural stem cells. *Development* 144, 635–648.
48. Gerace, D., Martiniello-Wilks, R., Nassif, N.T., Lal, S., Steptoe, R., and Simpson, A.M. (2017). CRISPR-targeted genome editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success? *Stem Cell Res. Ther.* 8, 62.
  49. Woo, D.H., Chen, Q., Yang, T.L., Glineburg, M.R., Hoge, C., Leu, N.A., Johnson, F.B., and Lengner, C.J. (2016). Enhancing a Wnt-telomere feedback loop restores intestinal stem cell function in a human organotypic model of dyskeratosis congenita. *Cell Stem Cell* 19, 397–405.
  50. Schwank, G., Koo, B.K., Sasselli, V., Dekkers, J.F., Heo, I., Demircan, T., Sasaki, N., Boymans, S., Cuppen, E., van der Ent, C.K., et al. (2013). Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. *Cell Stem Cell* 13, 653–658.
  51. Matano, M., Date, S., Shimokawa, M., Takano, A., Fujii, M., Ohta, Y., Watanabe, T., Kanai, T., and Sato, T. (2015). Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. *Nat. Med.* 21, 256–262.
  52. Drost, J., van Jaarsveld, R.H., Ponsioen, B., Zimmerlin, C., van Boxtel, R., Buijs, A., Sachs, N., Overmeer, R.M., Offerhaus, G.J., Begthel, H., et al. (2015). Sequential cancer mutations in cultured human intestinal stem cells. *Nature* 521, 43–47.
  53. Fessler, E., Drost, J., van Hooff, S.R., Linnekamp, J.F., Wang, X., Jansen, M., De Sousa E Melo, F., Prasetyanti, P.R., Ijspeert, J.E., Franitza, M., et al. (2016). TGF $\beta$  signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. *EMBO Mol. Med.* 8, 745–760.
  54. Verissimo, C.S., Overmeer, R.M., Ponsioen, B., Drost, J., Mertens, S., Verlaan-Klink, I., Gerwen, B.V., van der Ven, M., Wetering, M.V., Egan, D.A., et al. (2016). Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. *eLife* 5, e18489.
  55. Sohn, E.H., Jiao, C., Kaalberg, E., Cranston, C., Mullins, R.F., Stone, E.M., and Tucker, B.A. (2015). Allogenic iPSC-derived RPE cell transplants induce immune response in pigs: a pilot study. *Sci. Rep.* 5, 11791.
  56. Morizane, A., Doi, D., Kikuchi, T., Okita, K., Hotta, A., Kawasaki, T., Hayashi, T., Onoe, H., Shiina, T., Yamanaka, S., and Takahashi, J. (2013). Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. *Stem Cell Reports* 1, 283–292.
  57. Wu, Y., Liang, D., Wang, Y., Bai, M., Tang, W., Bao, S., Yan, Z., Li, D., and Li, J. (2013). Correction of a genetic disease in mouse via use of CRISPR-Cas9. *Cell Stem Cell* 13, 659–662.
  58. Xie, F., Ye, L., Chang, J.C., Beyer, A.I., Wang, J., Muench, M.O., and Kan, Y.W. (2014). Seamless gene correction of  $\beta$ -thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. *Genome Res.* 24, 1526–1533.
  59. Song, B., Fan, Y., He, W., Zhu, D., Niu, X., Wang, D., Ou, Z., Luo, M., and Sun, X. (2015). Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system. *Stem Cells Dev.* 24, 1053–1065.
  60. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. *Science* 326, 818–823.
  61. Dever, D.P., Bak, R.O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C.E., Pavel-Dinu, M., Saxena, N., Wilkens, A.B., Mantri, S., et al. (2016). CRISPR/Cas9  $\beta$ -globin gene targeting in human hematopoietic stem cells. *Nature* 539, 384–389.
  62. Li, H.L., Fujimoto, N., Sasakawa, N., Shirai, S., Ohkame, T., Sakuma, T., Tanaka, M., Amano, N., Watanabe, A., Sakurai, H., et al. (2015). Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. *Stem Cell Reports* 4, 143–154.
  63. Park, C.Y., Kim, D.H., Son, J.S., Sung, J.J., Lee, J., Bae, S., Kim, J.H., Kim, D.W., and Kim, J.S. (2015). Functional correction of large Factor VIII gene chromosomal inversions in hemophilia A patient-derived iPSCs using CRISPR-Cas9. *Cell Stem Cell* 17, 213–220.
  64. Xu, X., Tay, Y., Sim, B., Yoon, S.I., Huang, Y., Ooi, J., Utami, K.H., Ziaei, A., Ng, B., Radulescu, C., et al. (2017). Reversal of phenotypic abnormalities by CRISPR/Cas9-mediated gene correction in Huntington disease patient-derived induced pluripotent stem cells. *Stem Cell Reports* 8, 619–633.
  65. De Ravin, S.S., Li, L., Wu, X., Choi, U., Allen, C., Koontz, S., Lee, J., Theobald-Whiting, N., Chu, J., Garofalo, M., et al. (2017). CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. *Sci. Transl. Med.* 9, eaah3480.
  66. Alkhatib, G., Combadiere, C., Broder, C.C., Feng, Y., Kennedy, P.E., Murphy, P.M., and Berger, E.A. (1996). CC CKR5: a RANTES, MIP-1 $\alpha$ , MIP-1 $\beta$  receptor as a fusion cofactor for macrophage-tropic HIV-1. *Science* 272, 1955–1958.
  67. Bleul, C.C., Farzan, M., Choe, H., Parolin, C., Clark-Lewis, I., Sodroski, J., and Springer, T.A. (1996). The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. *Nature* 382, 829–833.
  68. Li, C., Guan, X., Du, T., Jin, W., Wu, B., Liu, Y., Wang, P., Hu, B., Griffin, G.E., Shattock, R.J., and Hu, Q. (2015). Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. *J. Gen. Virol.* 96, 2381–2393.
  69. Hou, P., Chen, S., Wang, S., Yu, X., Chen, Y., Jiang, M., Zhuang, K., Ho, W., Hou, W., Huang, J., and Guo, D. (2015). Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. *Sci. Rep.* 5, 15577.
  70. Xu, L., Yang, H., Gao, Y., Chen, Z., Xie, L., Liu, Y., Liu, Y., Wang, X., Li, H., Lai, W., et al. (2017). CRISPR/Cas9-mediated CCR5 ablation in human hematopoietic stem/progenitor cells confers HIV-1 resistance in vivo. *Mol. Ther.* 25, 1782–1789.
  71. Kang, H., Minder, P., Park, M.A., Mesquitta, W.-T., Torbett, B.E., and Slukvin, I.I. (2015). CCR5 disruption in induced pluripotent stem cells using CRISPR/Cas9 provides selective resistance of immune cells to CCR5-tropic HIV-1 virus. *Mol. Ther. Nucleic Acids* 4, e268.
  72. Ye, L., Wang, J., Beyer, A.I., Teque, F., Cradick, T.J., Qi, Z., Chang, J.C., Bao, G., Muench, M.O., Yu, J., et al. (2014). Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5 $\Delta$ 32 mutation confers resistance to HIV infection. *Proc. Natl. Acad. Sci. USA* 111, 9591–9596.
  73. Puschnik, A.S., Majzoub, K., Ooi, Y.S., and Carette, J.E. (2017). A CRISPR toolbox to study virus-host interactions. *Nat. Rev. Microbiol.* 15, 351–364.
  74. Liao, H.-K., Gu, Y., Diaz, A., Marlett, J., Takahashi, Y., Li, M., Suzuki, K., Xu, R., Hishida, T., Chang, C.J., et al. (2015). Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. *Nat. Commun.* 6, 6413.
  75. Stuckey, D.W., and Shah, K. (2014). Stem cell-based therapies for cancer treatment: separating hope from hype. *Nat. Rev. Cancer* 14, 683–691.
  76. Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A., and June, C.H. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. *Sci. Transl. Med.* 3, 95ra73.
  77. Rupp, L., Schumann, K., Roybal, K.T., Gate, R.E., Ye, C.J., Marson, A., and Lim, W.A. (2017). CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. *Sci Rep* 7, 737.
  78. Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S.J., Hamieh, M., Cunanan, K.M., Odak, A., Gönen, M., and Sadelain, M. (2017). Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. *Nature* 543, 113–117.
  79. Blum, R., Arumugam, A., Wu, J., Walcheck, B., and Kaufman, D. (2016). Engineering human pluripotent stem cell-derived natural killer cells to prevent CD16a shedding for enhanced anti-tumor killing. *Blood* 128, 1336.
  80. Hsu, P.D., Scott, D.A., Weinstein, J.A., Ran, F.A., Konermann, S., Agarwala, V., Li, Y., Fine, E.J., Wu, X., Shalem, O., et al. (2013). DNA targeting specificity of RNA-guided Cas9 nucleases. *Nat. Biotechnol.* 31, 827–832.
  81. Fu, Y., Foden, J.A., Khayter, C., Maeder, M.L., Reyon, D., Joung, J.K., and Sander, J.D. (2013). High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. *Nat. Biotechnol.* 31, 822–826.
  82. Kim, D., Kim, S., Kim, S., Park, J., and Kim, J.S. (2016). Genome-wide target specificities of CRISPR-Cas9 nucleases revealed by multiplex Digenome-seq. *Genome Res.* 26, 406–415.
  83. Cradick, T.J., Fine, E.J., Antico, C.J., and Bao, G. (2013). CRISPR/Cas9 systems targeting  $\beta$ -globin and CCR5 genes have substantial off-target activity. *Nucleic Acids Res.* 41, 9584–9592.



84. Wu, X., Scott, D.A., Kriz, A.J., Chiu, A.C., Hsu, P.D., Dadon, D.B., Cheng, A.W., Trevino, A.E., Konermann, S., Chen, S., et al. (2014). Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. *Nat. Biotechnol.* *32*, 670–676.
85. Veres, A., Gosis, B.S., Ding, Q., Collins, R., Ragavendran, A., Brand, H., Erdin, S., Cowan, C.A., Talkowski, M.E., and Musunuru, K. (2014). Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. *Cell Stem Cell* *15*, 27–30.
86. Smith, C., Gore, A., Yan, W., Abalde-Atristain, L., Li, Z., He, C., Wang, Y., Brodsky, R.A., Zhang, K., Cheng, L., and Ye, Z. (2014). Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. *Cell Stem Cell* *15*, 12–13.
87. Suzuki, K., Yu, C., Qu, J., Li, M., Yao, X., Yuan, T., Goebel, A., Tang, S., Ren, R., Aizawa, E., et al. (2014). Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. *Cell Stem Cell* *15*, 31–36.
88. Cradick, T.J., Qiu, P., Lee, C.M., Fine, E.J., and Bao, G. (2014). COSMID: A Web-based tool for identifying and validating CRISPR/Cas off-target sites. *Mol. Ther. Nucleic Acids* *3*, e214.
89. MacPherson, C.R., and Scherf, A. (2015). Flexible guide-RNA design for CRISPR applications using Protospacer Workbench. *Nat. Biotechnol.* *33*, 805–806.
90. Montague, T.G., Cruz, J.M., Gagnon, J.A., Church, G.M., and Valen, E. (2014). CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing. *Nucleic Acids Res.* *42*, W401–W407.
91. Moreno-Mateos, M.A., Vejnar, C.E., Beaudoin, J.D., Fernandez, J.P., Mis, E.K., Khokha, M.K., and Giraldez, A.J. (2015). CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo. *Nat. Methods* *12*, 982–988.
92. Naito, Y., Hino, K., Bono, H., and Ui-Tei, K. (2015). CRISPRdirect: software for designing CRISPR/Cas guide RNA with reduced off-target sites. *Bioinformatics* *31*, 1120–1123.
93. Upadhyay, S.K., and Sharma, S. (2014). SSFinder: high throughput CRISPR-Cas target sites prediction tool. *BioMed Res. Int.* *2014*, 742482.
94. Xu, H., Xiao, T., Chen, C.H., Li, W., Meyer, C.A., Wu, Q., Wu, D., Cong, L., Zhang, F., Liu, J.S., et al. (2015). Sequence determinants of improved CRISPR sgRNA design. *Genome Res.* *25*, 1147–1157.
95. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., and Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science* *337*, 816–821.
96. Ran, F.A., Hsu, P.D., Lin, C.Y., Gootenberg, J.S., Konermann, S., Trevino, A.E., Scott, D.A., Inoue, A., Matoba, S., Zhang, Y., and Zhang, F. (2013). Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. *Cell* *154*, 1380–1389.
97. Kleinstiver, B.P., Prew, M.S., Tsai, S.Q., Topkar, V.V., Nguyen, N.T., Zheng, Z., Gonzales, A.P., Li, Z., Peterson, R.T., Yeh, J.R., et al. (2015). Engineered CRISPR-Cas9 nucleases with altered PAM specificities. *Nature* *523*, 481–485.
98. Kleinstiver, B.P., Pattanayak, V., Prew, M.S., Tsai, S.Q., Nguyen, N.T., Zheng, Z., and Joung, J.K. (2016). High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. *Nature* *529*, 490–495.
99. Fu, Y., Sander, J.D., Reyon, D., Cascio, V.M., and Joung, J.K. (2014). Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. *Nat. Biotechnol.* *32*, 279–284.
100. Tsai, S.Q., Wyvekens, N., Khayter, C., Foden, J.A., Thapar, V., Reyon, D., Goodwin, M.J., Aryee, M.J., and Joung, J.K. (2014). Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. *Nat. Biotechnol.* *32*, 569–576.
101. Rutkauskas, M., Sinkunas, T., Songailiene, I., Tikhomirova, M.S., Siksnys, V., and Seidel, R. (2015). Directional R-loop formation by the CRISPR-Cas surveillance complex cascade provides efficient off-target site rejection. *Cell Rep.* *10*, 1534–1543.
102. Staals, R.H., Zhu, Y., Taylor, D.W., Kornfeld, J.E., Sharma, K., Barendregt, A., Koehorst, J.J., Vlot, M., Neupane, N., Varossieau, K., et al. (2014). RNA targeting by the type III-A CRISPR-Cas Csm complex of *Thermus thermophilus*. *Mol. Cell* *56*, 518–530.
103. Kleinstiver, B.P., Tsai, S.Q., Prew, M.S., Nguyen, N.T., Welch, M.M., Lopez, J.M., McCaw, Z.R., Aryee, M.J., and Joung, J.K. (2016). Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells. *Nat. Biotechnol.* *34*, 869–874.
104. Zetsche, B., Gootenberg, J.S., Abudayyeh, O.O., Slaymaker, I.M., Makarova, K.S., Essletzbichler, P., Volz, S.E., Joung, J., van der Oost, J., Regev, A., et al. (2015). Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. *Cell* *163*, 759–771.
105. Dang, Y., Jia, G., Choi, J., Ma, H., Anaya, E., Ye, C., Shankar, P., and Wu, H. (2015). Optimizing sgRNA structure to improve CRISPR-Cas9 knockout efficiency. *Genome Biol.* *16*, 280.
106. Jinek, M., East, A., Cheng, A., Lin, S., Ma, E., and Doudna, J. (2013). RNA-programmed genome editing in human cells. *eLife* *2*, e00471.
107. Kim, S., Kim, D., Cho, S.W., Kim, J., and Kim, J.S. (2014). Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. *Genome Res.* *24*, 1012–1019.
108. Gundry, M.C., Brunetti, L., Lin, A., Mayle, A.E., Kitano, A., Wagner, D., Hsu, J.L., Hoegenauer, K.A., Rooney, C.M., Goodell, M.A., and Nakada, D. (2016). Highly efficient genome editing of murine and human hematopoietic progenitor cells by CRISPR/Cas9. *Cell Rep.* *17*, 1453–1461.
109. Lin, S., Staahl, B.T., Alla, R.K., and Doudna, J.A. (2014). Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. *eLife* *3*, e04766.
110. Houseley, J., and Tollervey, D. (2009). The many pathways of RNA degradation. *Cell* *136*, 763–776.
111. Hendel, A., Bak, R.O., Clark, J.T., Kennedy, A.B., Ryan, D.E., Roy, S., Steinfeld, I., Lunstad, B.D., Kaiser, R.J., Wilkens, A.B., et al. (2015). Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. *Nat. Biotechnol.* *33*, 985–989.
112. Yu, C., Liu, Y., Ma, T., Liu, K., Xu, S., Zhang, Y., Liu, H., La Russa, M., Xie, M., Ding, S., and Qi, L.S. (2015). Small molecules enhance CRISPR genome editing in pluripotent stem cells. *Cell Stem Cell* *16*, 142–147.
113. Srivastava, M., Nambiar, M., Sharma, S., Karki, S.S., Goldsmith, G., Hegde, M., Kumar, S., Pandey, M., Singh, R.K., Ray, P., et al. (2012). An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. *Cell* *151*, 1474–1487.
114. Maruyama, T., Dougan, S.K., Truttmann, M.C., Bilate, A.M., Ingram, J.R., and Ploegh, H.L. (2015). Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. *Nat. Biotechnol.* *33*, 538–542.
115. Song, J., Yang, D., Xu, J., Zhu, T., Chen, Y.E., and Zhang, J. (2016). RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency. *Nat. Commun.* *7*, 10548.
116. Chu, V.T., Weber, T., Wefers, B., Wurst, W., Sander, S., Rajewsky, K., and Kühn, R. (2015). Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. *Nat. Biotechnol.* *33*, 543–548.
117. Zhong, Q., Chen, C.F., Chen, P.L., and Lee, W.H. (2002). BRCA1 facilitates microhomology-mediated end joining of DNA double strand breaks. *J. Biol. Chem.* *277*, 28641–28647.
118. Nakade, S., Tsubota, T., Sakane, Y., Kume, S., Sakamoto, N., Obara, M., Daimon, T., Sezutsu, H., Yamamoto, T., Sakuma, T., and Suzuki, K.T. (2014). Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR/Cas9. *Nat. Commun.* *5*, 5560.
119. Thibault, S.T., Singer, M.A., Miyazaki, W.Y., Milash, B., Dompe, N.A., Singh, C.M., Buchholz, R., Demsky, M., Fawcett, R., Francis-Lang, H.L., et al. (2004). A complementary transposon tool kit for *Drosophila melanogaster* using P and piggyBac. *Nat. Genet.* *36*, 283–287.
120. Wang, G., Yang, L., Grishin, D., Rios, X., Ye, L.Y., Hu, Y., Li, K., Zhang, D., Church, G.M., and Pu, W.T. (2017). Efficient, footprint-free human iPSC genome editing by consolidation of Cas9/CRISPR and piggyBac technologies. *Nat. Protoc.* *12*, 88–103.
121. Ramakrishna, S., Kwaku Dad, A.B., Beloor, J., Gopalappa, R., Lee, S.K., and Kim, H. (2014). Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. *Genome Res.* *24*, 1020–1027.



122. Hammer, R.E., Pursel, V.G., Rexroad, C.E., Jr., Wall, R.J., Bolt, D.J., Ebert, K.M., Palmiter, R.D., and Brinster, R.L. (1985). Production of transgenic rabbits, sheep and pigs by microinjection. *Nature* 315, 680–683.
123. Gossler, A., Doetschman, T., Korn, R., Serfling, E., and Kemler, R. (1986). Transgenesis by means of blastocyst-derived embryonic stem cell lines. *Proc. Natl. Acad. Sci. USA* 83, 9065–9069.
124. Costa, M., Dottori, M., Sourris, K., Jamshidi, P., Hatzistavrou, T., Davis, R., Azzola, L., Jackson, S., Lim, S.M., Pera, M., et al. (2007). A method for genetic modification of human embryonic stem cells using electroporation. *Nat. Protoc.* 2, 792–796.
125. Androutsellis-Theotokis, A., Leker, R.R., Soldner, F., Hoepfner, D.J., Ravin, R., Poser, S.W., Rueger, M.A., Bae, S.K., Kittappa, R., and McKay, R.D. (2006). Notch signalling regulates stem cell numbers in vitro and in vivo. *Nature* 442, 823–826.
126. Zou, J., Maeder, M.L., Mali, P., Pruetz-Miller, S.M., Thibodeau-Beganny, S., Chou, B.-K., Chen, G., Ye, Z., Park, I.H., Daley, G.Q., et al. (2009). Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. *Cell Stem Cell* 5, 97–110.
127. Yin, H., Song, C.Q., Dorkin, J.R., Zhu, L.J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., et al. (2016). Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. *Nat. Biotechnol.* 34, 328–333.
128. Jiang, C., Mei, M., Li, B., Zhu, X., Zu, W., Tian, Y., Wang, Q., Guo, Y., Dong, Y., and Tan, X. (2017). A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and psc9 in vivo. *Cell Res.* 27, 440–443.
129. Buchschacher, G.L., Jr., and Wong-Staal, F. (2000). Development of lentiviral vectors for gene therapy for human diseases. *Blood* 95, 2499–2504.
130. Zufferey, R., Dull, T., Mandel, R.J., Bukovsky, A., Quiroz, D., Naldini, L., and Trono, D. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. *J. Virol.* 72, 9873–9880.
131. Rubinson, D.A., Dillon, C.P., Kwiatkowski, A.V., Sievers, C., Yang, L., Kopinja, J., Rooney, D.L., Zhang, M., Ihrig, M.M., McManus, M.T., et al. (2003). A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. *Nat. Genet.* 33, 401–406.
132. Toledo, C.M., Ding, Y., Hoellerbauer, P., Davis, R.J., Basom, R., Girard, E.J., Lee, E., Corrin, P., Hart, T., Bolouri, H., et al. (2015). Genome-wide CRISPR-Cas9 screens reveal loss of redundancy between PKMT1 and WEE1 in glioblastoma stem-like cells. *Cell Rep.* 13, 2425–2439.
133. Kabadi, A.M., Ousterout, D.G., Hilton, I.B., and Gersbach, C.A. (2014). Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. *Nucleic Acids Res.* 42, e147.
134. Yang, L., Guell, M., Byrne, S., Yang, J.L., De Los Angeles, A., Mali, P., Aach, J., Kim-Kiselak, C., Briggs, A.W., Rios, X., et al. (2013). Optimization of scarless human stem cell genome editing. *Nucleic Acids Res.* 41, 9049–9061.
135. Cornu, T.L., and Cathomen, T. (2007). Targeted genome modifications using integrase-deficient lentiviral vectors. *Mol. Ther.* 15, 2107–2113.
136. Muzyczka, N. (1992). Use of adeno-associated virus as a general transduction vector for mammalian cells. *Curr. Top. Microbiol. Immunol.* 158, 97–129.
137. Zlotorynski, E. (2016). Genome engineering: NHEJ and CRISPR-Cas9 improve gene therapy. *Nat. Rev. Mol. Cell Biol.* 18, 4.
138. Xiao, X., Li, J., and Samulski, R.J. (1998). Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. *J. Virol.* 72, 2224–2232.
139. Zolotukhin, S., Byrne, B.J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R.J., and Muzyczka, N. (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. *Gene Ther.* 6, 973–985.
140. Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. *Annu. Rev. Virol.* 1, 427–451.
141. Bengtsson, N.E., Hall, J.K., Odom, G.L., Phelps, M.P., Andrus, C.R., Hawkins, R.D., Hauschka, S.D., Chamberlain, J.R., and Chamberlain, J.S. (2017). Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. *Nat. Commun.* 8, 14454.
142. Kotterman, M.A., and Schaffer, D.V. (2014). Engineering adeno-associated viruses for clinical gene therapy. *Nat. Rev. Genet.* 15, 445–451.
143. Tabeordbar, M., Zhu, K., Cheng, J.K.W., Chew, W.L., Widrick, J.J., Yan, W.X., Maesner, C., Wu, E.Y., Xiao, R., Ran, F.A., et al. (2016). In vivo gene editing in dystrophic mouse muscle and muscle stem cells. *Science* 351, 407–411.
144. Ran, F.A., Cong, L., Yan, W.X., Scott, D.A., Gootenberg, J.S., Kriz, A.J., Zetsche, B., Shalem, O., Wu, X., Makarova, K.S., et al. (2015). In vivo genome editing using Staphylococcus aureus Cas9. *Nature* 520, 186–191.
145. Yang, Y., Wang, L., Bell, P., McMenamin, D., He, Z., White, J., Yu, H., Xu, C., Morizono, H., Musunuru, K., et al. (2016). A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. *Nat. Biotechnol.* 34, 334–338.
146. Mingozzi, F., and High, K.A. (2013). Immune responses to AAV vectors: overcoming barriers to successful gene therapy. *Blood* 122, 23–36.
147. Han, X., Liu, Z., Jo, M.C., Zhang, K., Li, Y., Zeng, Z., Li, N., Zu, Y., and Qin, L. (2015). CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation. *Sci. Adv.* 1, e1500454.